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The  present  study  aimed  to  analyze  the  expression  proﬁle  of  the microRNAs  previously  described  as
associated  with  childhood  ALL, miR-92a,  miR-100,  miR-125a-5p,  miR-128a,  miR-181b,  miR-196b  and
let-7e, and  their  association  with  biological/prognostic  features  in 128  consecutive  samples  of  childhoodccepted 7 October 2011
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acute  lymphoblastic  leukemia  (ALL)  by quantitative  real-time  PCR.  A signiﬁcant  association  was  observed
between  higher  expression  levels  of  miR-196b  and  T-ALL,  miR-100  and  patients  with  low  white  blood
cell  count  at  diagnosis  and  t(12;21)  positive  ALL. These  ﬁndings  suggest  a potential  activity  of  these
microRNAs  in pediatric  ALL  biology.
© 2011 Elsevier Ltd. Open access under the Elsevier OA license. 
rognostic features
. Introduction
Acute lymphoblastic leukemia (ALL) represents the most com-
on  type of childhood malignant neoplasia and, despite the
igniﬁcant progress in current treatment, 20–30% of affected chil-
ren relapse and the causes are still uncertain [1].  ALL is a
eterogeneous disease, composed of many subtypes that represent
ifferent clinical behaviors and need different therapy schemes [2];
owever, the complex mechanism driving to distinct outcomes in
ach subtype is still poorly understood.
In this context, it is important to study microRNAs (miR-
As), small (17–25 nucleotides) single-stranded noncoding RNAs
hat function predominantly as sequence-targeted modiﬁers of
ene expression through translational repression. Currently, more
han 1000 miRNAs have been described for the human genome
nd, although most of them do not have established func-
ion, the association between the disruption of their expression
nd tumor progression and aggressiveness is widely accepted
3,4]. The miRNAs play an important role in the regulation of
ormal hematopoiesis and their disruption could contribute to
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aulo, Brazil. Tel.: +55 16 3602 2672; fax: +55 16 3602 2700.
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Open access under the Elsevier OA license. leukemogenesis [5–8]. Few studies have been conducted until now
concerning the role of miRNA in childhood ALL [9–14]. These
studies have shown that miRNA expression analysis may help to
understand the development of different phenotypes and the bio-
logical functions of these miRNAs in childhood ALL.
Based on this information, we aimed to evaluate the expres-
sion of miRNAs previously reported to be differentially expressed
in childhood ALL [9] (miR-92a, miR-100, miR-125a-5p, miR-128a,
miR-181b, miR-196b and let-7e), in consecutively diagnosed bone
marrow samples from children with ALL treated according to the
GBTLI-ALL 99 protocol and to correlate their expression levels with
biological/prognostic features.
2. Materials and methods
2.1. Patients
Bone marrow (BM) samples were obtained at diagnosis from 128 consecutive
patients with childhood ALL classiﬁed and treated from January 2002 to May  2005
according to the Brazilian Childhood Leukemia Treatment Group (GBTLI ALL-99)
protocol [15,16] at two different treatment centers. In addition, 11 normal BM
samples from children without hematological diseases (aged 1 month to 13 years)
were analyzed. The study was approved by the National Research Ethics Committee
(CONEP, No. 7329/2009) and was  based on the Helsinki convention criteria. Sam-
ples were collected after written informed consent was obtained from the persons
responsible for the children.
The diagnosis was made by standard morphological analysis and ﬂow cytometry
in  BM at diagnosis, with all patients presenting more than 70% of blasts cells. Among
the 128 ALL patients studied, 108 (84.4%) had B-derived ALL (pro-B ALL in 10 cases
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Table 1
Minimum, maximum and median microRNA expression levels in normal bone mar-
row and in ALL samples.
microRNA Normal BM (n = 11) ALL (n = 128) P value
Median (range) Median (range)
miR-92a 0.97 (0.45–3.91) 0.77 (0.08–5.04) 0.07
miR-100 1.04 (0.34–3.90) 0.21 (0.002–10.76) <0.01
miR-125a-5p 1.27 (0.48–4.25) 0.80 (0.01–29. 33) 0.37
miR-128a 1.02 (0.57–2.23) 4.32 (0.16–167.91) <0.01
miR-181b 1.41 (0.33–3.40) 5.06 (0.07–45.09) <0.01
miR-196b 1.07 (0.29–3.70) 0.03 (0.001–65.68) <0.01
let-7e 1.16 (0.54–3.25) 0.59 (0.04–5.15) <0.01
T
C
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nd common-ALL/pre-B ALL in 98), and 20 (15.6%) had T-ALL; 69 were boys and 59
ere girls ranging in age from 13 months to 17 years (median 5.2 years). The white
lood cell count (WBC) ranged from 800 to 849,000/mm3 (median: 17,700/mm3).
even patients presented t(9;22), ﬁve t(4;11), twenty-one t(12;21) and one t(1;19)
as  detected by reverse transcription (RT)-PCR [17]. Conventional G-band kary-
typing was performed in 62 patients, with 12 of them presenting a hyperdiploid
aryotype.
Patients were characterized as poor responders, regardless of the initial risk
roup, if they met  one or more of the following criteria during the phase of remission
nduction: WBC  > 5000/mm3 on day 7 (D7) as a proxy for peripheral blast count, M3
one  marrow (>25% blasts) on day 14 (D14), or M2/M3  bone marrow (>5 and 25%
lasts, respectively) on day 28 (D28) [16]. Eighty-three patients were classiﬁed as
igh risk (64.8%) and 20 (15.3%) as poor responders.
The time of follow-up of patients in complete clinical remission ranged from 34
o  74 months, with a median observation of 56 months. Unfavorable events (death
ue to any cause or relapse) occurred in 31 patients (24.2%). Of these, 17 relapsed
nd 14 died during induction (n = 9) or in clinical remission (n = 5). Among these
atients, all casualties were associated with treatment complications: sepsis (n = 12)
nd  hemorrhagic disorders (n = 2).
Minimal residual disease (MRD) was detected by a simpliﬁed PCR method with
onsensus primers for T cell receptor (TCR) and immunoglobulin (Ig) gene rearrange-
ents on days 14 and 28, as previously described [15]. The 5 years event free survival
ccording clinical and biological features are shown in supplemental Table S1.
.2.  RNA extraction, cDNA synthesis and quantitative real-time PCR (RQ-PCR)
BM  mononucleated cells were separated by a Ficoll-Hypaque centrifugation gra-
ient and the total cellular RNA was extracted from BM samples using Trizol Reagent
Invitrogen, Carlsbad, CA, USA). The RNA of each sample was  stored in DEPC-treated
ater at −80 ◦C and, before use; the quantity and quality of samples were eval-
ated with an ND-1000 NanoDrop spectrophotometer (NanoDrop Technologies).
otal RNA (100 ng) was retrotranscribed with microRNA-speciﬁc primers using a
aqMan microRNA reverse transcription kit (Applied Biosystems, Foster City, CA),
nd qRT-PCR was  then performed using Taqman® microRNA assays according to the
anufacturer’s protocol.
The microRNA levels of miR-92a, miR-100, miR-125a-5p, miR-128a, miR-181b,
iR-196b and let-7e were measured using the ABI 7500 Real Time PCR System
PE Applied Biosystems). The relative expression was  calculated using the 2−CT
ethod [18] with two internal controls, small nuclear RNU6B and RNU48, used to
ormalize the cDNA levels. The ampliﬁcation efﬁciency of each miRNA and endoge-
ous probes was  92–101%, and the plot of cDNA dilutions versus delta Ct was close
o zero (slope ≤ ±0.1). The mean expression in the 11 normal bone marrow samples
as  used as calibrator.
Real time PCR was performed in duplicate and a standard deviation (SD) of <0.5
etween duplicates was  accepted. A blank control was  run in parallel to determine
he absence of contamination within each experiment..3. Statistical analysis
The association between the variables analyzed (age, WBC  count at diagno-
is, immunophenotype, risk group, molecular cytogenetics, hyperdiploid karyotype,
able 2
orrelation among analyzed microRNA expressions in childhood ALL patients.
mir92 mir100 mir125 
mir-92a
CC 1.00 0.04 0.21 
P  value – 0.68 0.02 
mir-100
CC  0.04 1.00 0.31 
P  value 0.68 – 0.00 
mir-125a-5p
CC  0.21 0.31 1.00 
P  value 0.02 0.00 – 
mir-128a
CC 0.37  0.02 0.26 
P  value 0.00 0.78 0.00 
mir-181b
CC  0.43 0.06 0.12 
P  value 0.00 0.53 0.16 
mir-196b
CC  0.10 0.13 −0.06 
P  value 0.25 0.13 0.50 
let-7e
CC  0.47 −0.02 0.32 
P  value 0.00 0.83 0.00 
C, Spearman’s correlation coefﬁcient. Bold value indicates statistically signiﬁcant (P < 0.0P value calculated by the Mann–Whitney test. Bold value indicates statistically sig-
niﬁcant (P < 0.05).
BM,  bone marrow.
bone marrow status at day 28, MRD  at day 14 and 28) and microRNA expression
levels was  determined by the Mann–Whitney test.
For survival analysis, patients were stratiﬁed into values below and above the
median, the quartiles (P25 and P75) and the average of expression levels in normal
bone marrow. The Kaplan Meier curves and log rank test were used to estimate
event-free survival (5-year EFS), which was calculated from the date of complete
continuous remission (CCR) to the last follow-up, or unfavorable event (induction
failure, relapse and/or death due to any cause). Patients who did not attain CCR or
died during induction were considered as an unfavorable event at time zero.
The  correlation between the expression values of the microRNAs was  deter-
mined by the Spearman correlation coefﬁcient. Data were analyzed statistically
using the Statistical Package for the Social Sciences (SPSS) software for Windows,
version 15.0 (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Expression of microRNAs in ALL and in normal bone marrow
ALL samples showed a lower expression of miR-100 (P < 0.01),
miR-196b (P < 0.01) and let-7e (P < 0.01) and a higher expression of
miR-128 (P < 0.01) and miR-181 (P < 0.01) compared to control BM
samples. The expression of miR-92a and miR-125a-5p was  similar
for both groups (Table 1).
3.2. Relation between microRNA expression and
clinical/biological featuresThe microRNAs studied presented a wide variability of expres-
sion in ALL patients (Table 1). A signiﬁcant positive correlation
was observed by the Spearman’s correlation test between miR-92a,
mir128 mir181 mir196 let7e
0.37 0.43 0.10 0.47
0.00 0.00 0.25 0.00
0.02 0.06 0.13 −0.02
0.78 0.53 0.13 0.83
0.26 0.12 −0.06 0.32
0.00 0.16 0.50 0.00
1.00 0.50 −0.03 0.44
– 0.00 0.72 0.00
0.50 1.00 −0.13 0.42
0.00 – 0.15 0.00
−0.03 −0.13 1.00 0.24
0.72 0.15 – 0.01
0.44 0.42 0.24 1.00
0.00 0.00 0.01 –
5).
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Fig. 1. Relative expression levels of miRNAs in ALL patients stratiﬁed according to biological and clinical features. (A) miR-196b expression in patients positive (left) or
negative (right) for the presence of T-cell phenotype (P = 0.01). (B) MiR-100 expression in ALL patients with less than 50,000/mm3 white blood cells (WBC) (left) or more than
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xpression in patients negative (left) or positive (right) for the presence of hyperdip
iR-128a, miR-181b and let-7e expression; miR-125a-5p, miR-
2a, miR-128a and let-7e and miR-100; and miR-196b and let-7e
Table 2).
A higher MiR-196b expression was found in T-ALL (P = 0.01).
iR-100 expression was higher in patients who presented a WBC
ount at diagnosis <50,000/mm3 (P = 0.01). In the group of B-cell
LL patients, higher miR-100 expression was associated with the
resence of t(12;21) (P = 0.04) and the absence of a hyperdiploid
aryotype (P = 0.04) (Fig. 1) (Table S2).
The presence of t(4;11) was associated with miR-181b (P = 0.02)
nd miR-128a (P = 0.03) (Fig. 2).
.3. Relation between microRNA expression and treatment
esponse parameters
Despite the low number of patients in each group, the expres-
ion of miR-125a-5p (P = 0.02) and let-7e (P = 0.04) was  lower in
atients who presented BM status M2/M3  at day 28 of induc-
ion therapy (n = 7). Additionally, let-7e expression was  higher in
atients with MRD  at D14 (P = 0.02) (n = 12) (Fig. 3) (Tables S3–S5).
In order to analyze a possible correlation between the expres-
ion of the mRNAs analyzed and EFS the patients were divided
nto two groups using the values below and above the median ast) or positive (right) for the presence of 12;21 translocation (P = 0.04). (D) MiR-100
 (P = 0.04). Mann–Whitney test.
cut-off. None of the miRNAs analyzed were associated with 5y EFS
(Table S6). The same was true when the quartiles (P25 and P75)
and the average of expression levels in control BM were used as a
cut-off between low and high expression (data not shown).
4. Discussion
MicroRNAs are associated with the regulation of normal
hematopoiesis and their disruption has been related to many types
of cancer, including hematological malignancies, but little is known
about their effects on childhood ALL. In the present study, pedi-
atric ALL BM samples showed lower expression levels of miR-100,
miR-196b and let-7e, while miR-128a and miR-181b were over-
expressed in patients when compared to normal pediatric BM
samples. Similar to our results, miR-128a and miR-181 have been
previously reported to be up-regulated in ALL compared to normal
donors [10] and also to normal CD34+ progenitor cells [9].  Addi-
tionally, down-regulation of miR-100, miR-196b and let-7e was
demonstrated in B-ALL without translocations compared to CD34+
cells [9].  Other studies have also shown that some of the miRNA
analyzed here inﬂuence hematopoietic differentiation including
miR181 [19], miR196a [20,21], and mir125 [11,22,23].  However,
since normal BM and CD34+ cells do not reproduce exactly the
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(ig. 2. Relative expression levels of miRNAs in ALL patients stratiﬁed according to
right)  for the presence of t(4;11) (P = 0.03). (B) MiR-181b expression in patients po
ormal counterpart of ALL BM,  these results should be viewed with
aution.
Besides the described pattern of expression in normal progen-
tor cells, these miRNAs have also been found to be differentially
xpressed in different subtypes of ALL [9]. These genes could also
ave led to inappropriate expression of proteins that act as tumor
uppressors or oncogenes. Some of them such as let-7e, miR100 and
iR196b have been reported to have potential tumor suppressive
unction [20,24,25],  while miR181 targets oncoproteins [24].
Analysis of the correlation of expression levels among the genes
nder study by the Spearman’s correlation coefﬁcient showed a
igniﬁcant positive correlation between some of them, suggesting
 possible co-regulation in childhood ALL.
Regarding the biological features, miR-196b analyses demon-
trated higher expression in T-cell ALL when compared to B-cell
atients. The association between miR-196b and ALL has been
eported in association with t(4;11) [9,26].  In the present study,
espite a higher expression in patients with t(4;11), this difference
as not signiﬁcant. High expression of miR-196b is not exclusively
nduced by MLL  chimeras, but has been also correlated with other
eukemia types, including T-cell ALL, with increased HOXA gene
xpression [27].
MiR-196b is encoded in the HOXA-cluster, mapped between the
OXA9 and HOXA10 genes and is most likely co-regulated in ALL
27]. Although the involvement of HOXA genes in the survival and
ig. 3. Relative expression levels of miRNAs in ALL patients stratiﬁed according to treatme
s  M1  (left) or M2/M3 (right) analyzed on day 28 (P = 0.02). (B) Let-7e expression in patie
P  = 0.04). (C) Let-7e expression in patients with negative minimal residual disease (left) oresence of t(4;11). (A) MiR-128a expression in patients positive (left) or negative
(left) or negative (right) for the presence of t(4;11) (P = 0.02). Mann–Whitney test.
proliferation rates of leukemia cells is generally recognized [28],
the overexpression of mir-196b in bone marrow progenitor cells
also leads to increased proliferative capacity and survival [26]. In
spite of this, its role in leukemia is still controversial, since there
are descriptions of its involvement in the regulation of oncopro-
teins such as ERG and c-myc, suggesting a tumor suppressor activity
[20,21].  Noteworthy, miR-196b has been associated with the down-
regulation of c-myc in B-cell ALL [20], an event not occurring in
T-cell ALL as a consequence of mutations in the 3′-untranslated
region (3′-UTR) of this gene as reported for some cell lines and
patient samples [29]. It is interesting to point that these subtypes
related to higher miR196b expression are associated with a poor
clinical outcome.
We found lower levels of miR-100 expression in ALL patients as
a whole and even signiﬁcantly lower levels in patients with a WBC
count higher than 50,000/mm3. Additionally, increased miR-100
expression was associated with the presence of t(12;21), biological
features classically associated with a good outcome. The associ-
ation between miR-100 expression and t(12;21) patients agrees
with previous studies [30]. Furthermore, we  found an association
between low miR-100 expression and hyperdiploid karyotypes,
that are infrequent in t(12;21) ALL (∼1%) [31]. This fact may  rein-
force a t(12;21) speciﬁc regulation of miR-100. Likewise, previous
reports on oral cancer have demonstrated that forced expression
of miR-100 results in decreased proliferation [32]. Furthermore,
nt parameters. (A) miR-125a-5p expression in patients with bone marrow classiﬁed
nts with bone marrow classiﬁed as M1  (left) or M2/M3  (right) analyzed on day 28
r positive analyzed on day 14 (P = 0.02). Mann–Whitney test.
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iR-100 is known to regulate central elements in signaling path-
ays involved in cell growth control and proliferation such as PLK1,
GF2R and FRAP1/mTOR [33–35].  In contrast, a positive correlation
etween miR-100 and cell growth has been demonstrated in vitro
or AML, where this mirRNA is required for cell growth through
he regulation of the tumor suppressor RBSP3 [36]. Of note, when
ompared to ALL and normal cells, miR-100 levels are exceedingly
igher in AML  [10], suggesting a different responsibility for each
ineage.
In the present study, some miRNAs were associated with other
linical and biological features. Among them, lower expression of
iR-125a-5p was associated with M2/M3  bone marrow status on
28 (n = 7).
MiR-125a expression seems to be conﬂicting in different tumors,
ith hyperexpression occurring in lung squamous cell carcinoma
nd hypoexpression in glioblastomas, medulloblastomas and oral
ancer [37–39]. In hematopoietic malignancies, lower expression
as been related to HTLV-1-associated acute adult T-cell leukemia
40]. Speciﬁcally, miR-125a-5p is an independent prognostic factor
n gastric cancer and inhibits proliferation in vitro [41]. Further-
ore, this miRNA induces apoptosis by activating p53 in lung
ancer cells [42].
The results of miRNA let-7e expression were inconsistent when
linical outcome was considered. While this expression was  asso-
iated with a good morphological response in bone marrow at D28
n = 7), it was also associated with the presence of higher levels of
RM on D14 (n = 12). These discrepancies could be related to the
mall number of cases analyzed and further studies are necessary to
etermine the relationship between this miRNA and ALL outcome.
Literature data also seem to be controversial about the tumor
uppressor role of let-7e. Lower expression levels have been
escribed for malignant mesotheliomas [43], as opposed to overex-
ression in retinoblastomas [44]. Nevertheless, there is compelling
vidence of down-regulation of let-7e involvement in resistance to
etuximab in colorectal cancer and to Gemcitabine in pancreatic
nd ovarian cancer [45–47],  with let-7e being a regulator of the
roto-oncogene MYCN [48].
Our study also points to an association between miR-181b and
iR-128a expression and t(4;11) ALL. Due to the small number
f cases carrying this translocation, additional studies on a higher
umber of cases are necessary to corroborate these data.
In conclusion, miR-196b expression was found to be higher in
-ALL and miR-100 expression was higher in patients with a WBC
ount <50,000/mm3 at diagnosis and in t(12;21)-positive patients.
hese ﬁndings suggest a potential role of these microRNAs in spe-
iﬁc subtypes of pediatric ALL and in the development of different
henotypes. Further studies are needed to corroborate and extend
ur results.
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